Scientific Publications
Rehaume Linda M., Cross Jennifer L., Huizinga Robert B, Viel John J. Voclosporin Inhibits Calcineurin and T Cell Activation at Dose Levels Clinically Relevant for the Treatment of Lupus Nephritis. NKF Spring Clinical Meetings 2023.
Waddingham Nicola, Rosales Amber, Cheung Gigi, Potter Blake, Palmen Mary, Collins Christopher. Trial in Progress: Voclosporin in Adolescents with Lupus Nephritis (VOCAL). NKF Spring Clinical Meetings 2023.
Tatsuya Atsumi, Tien-Tsai Cheng, Tuyen Do Gia, Shunsuke Furuta, Harold Michael P. Gomez, Llewellyn T. Hao, Ngoc Phuong Thao Huynh, Michihito Kono, Sandra Navarra, Kajohnsak Noppakun, Kenji Oku, Bernadette Reyes, Bancha Satirapoj: Long-term Safety and Efficacy of Voclosporin in Asian Patients with Lupus Nephritis. APLAR. 2022.
Tatsuya Atsumi, Tien-Tsai Cheng, Tuyen Do Gia, Shunsuke Furuta, Harold Michael P. Gomez, Llewellyn T. Hao, Ngoc Phuong Thao Huynh, Michihito Kono, Sandra Navarra, Kajohnsak Noppakun, Kenji Oku, Bernadette Reyes, Bancha Satirapoj: Long-term Safety and Efficacy of Voclosporin in Asian Patients with Lupus Nephritis. APLAR. 2022.
Menn-Josephy H, Palmen M, Truman M, Leher H: Efficacy and Safety of Voclosporin Over Three Years in Patients with Severe Lupus Nephritis. J Am Soc Nephrol 33, 2022: Page 33.
Link: 2022 ASN Abstract
Tagoe KJ, Orujov E, Baker MG, Cipolla L, McLemore J, Leher H: Enlight-LN: A Prospective Observational Registry of Patients Treated with Voclosporin for Lupus Nephritis in the United States. J Am Soc Nephrol 33, 2022.
Link: 2022 ASN Abstract
Askanase A, Randhawa S, Lisk L, Mina-Osorio P. Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9).
Mackay M, Truman M, England N, Birardi V, Mina-Osorio P. Efficacy of Voclosporin in Recent Onset Lupus Nephritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9).
Link: 2021 ACR Abstract
Caster DJ, Solomons N, Randhawa S, Huizinga RB. AURORA Phase 3 Trial Demonstrates Voclosporin Statistical Superiority Over Standard of Care in Lupus Nephritis. Nephrology Dialysis Transplantation. 35 (suppl 3).
Link to abstract and downloadable .pdf here.
Gibson K, Parikh S, Saxena A, Solomons N, Randhawa S. AURORA Phase 3 Trial Demonstrates Voclosporin Statistical Superiority Over Standard of Care in Lupus Nephritis (LN). American Journal of Kidney Diseases.2020. 75(No. 5):819-819.
Link: 2020 NKF Abstract
Ginzler E, Kaplan J, Lisk L, Federico R, Solomons N, Huizinga R. Integrated Efficacy of the AURORA-1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinuria Reduction in the Presence of Low-Dose Steroids. Arthritis Rheumatology. 2020. 72(suppl 10).
Link: 2020 ACR Abstract
Atsumi T, Navarra S, Randhawa S, Solomons N. Voclosporin Has Demonstrated Efficacy in Asian Patients With Lupus Nephritis. APLAR. 2020.
van Gelder T, Huizinga R, Solomons N, Lisk L. Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE. Arthritis Rheumatology. 2020. 72(suppl 10).
Link: 2020 ACR Abstract
Arriens C, Polyakova S, Adzerikho I, Randhawa S, Solomons N. AURORA Phase 3 Study Demonstrates Voclosporin Statistical Superiority Over standard of Care in Lupus Nephritis. Annals of the Rheumatic Diseases. 2020. 79(suppl 1): 172‐173.
Link: 2020 EULAR Abstract
Rovin B, Parikh S, Huizinga RB, Solomons N, Randhawa S. Management of Lupus Nephritis (LN) with Voclosporin (VCS): An Update from a Pooled Analysis of 534 Patients. Journal of the American Society of Nephrology. 2020. 31:594.
Link: 2020 ASN Abstract
van Gelder T, Huizinga RB, Noukens J, Lisk L, Solomons N. Use of TDM Does Not Add Clinical Value for Voclosporin in Patients with Lupus Nephritis. Journal of the American Society of Nephrology. 2020. 31:594.
Link: 2020 ASN Abstract
Teng YO, Parikh SV, Saxena A, Solomons N, Huizinga RB. AURORA Phase 3 Study Demonstrates Voclosporin Statistical Superiority Over Standard of Care in Lupus Nephritis (LN). Lupus Science and Medicine. 2020. 7(suppl 1).
Link: 2020 LUPUS Abstract
Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AE, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez‐Perez NN, Arriens C. Safety and efficacy of long‐term Voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis & Rheumatology (2024);76(1):59-67.
Link: 2024 Manuscript
Wei KY, van Heugten MH, van Megen WH, van Veghel R, Rehaume LM, Cross JL, Viel JJ, van Willigenburg H, Silva PH, Danser AJ, de Baaij JH. Calcineurin inhibitor effects on kidney electrolyte handling and blood pressure: tacrolimus versus voclosporin. Nephrol Dial Transplant (2024); https://doi.org/10.1093/ndt/gfae119.
Link: 2024 Manuscript
Afshinnia F, Rajendiran TM, Byun J, Arnipalli MS, Rehaume LM, Cross JL, Huizinga RB, Pennathur S. Voclosporin Induces Systemic Lipidomic Alterations: Implications for Lupus Nephritis Remission. Kidney Int Rep (2024); https://doi.org/10.1016/j.ekir.2024.04.069.
Link: 2024 Manuscript
Arriens C, Teng, YKO, Ginzler EM, Parikh SV, Askanase AD, Saxena A, Gibson K, Caster D, Atsumi T, Lisk L, Randhawa S, Gluck R, Solomons N, Huizinga RB. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care & Research. 2022; Aug 30.
Link: 2022 Manuscript
Dall’Era M, Kenneth Kalunian K, Eaddy M, Augustina Ogbonnaya A, Farrelly E, Turowski E, Birardi V, Solomons N, Randhawa S, Mina-Osorio P. Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States. J Manag Care Spec Pharm. 2022; Oct.
Link: 2022 Manuscript
van Gelder T, Huizinga RB, Lisk L Solomons N. Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. Nephrol Dial Transplant (2022) 37: 917–922.
Link here.
T, Navarra S, Randhawa S, Solomons N. Voclosporin Has Demonstrated Efficacy in Asian Patients With Lupus Nephritis. APLAR. 2020.
Teng YO, Parikh SV, Saxena A, Solomons N, Huizinga RB. AURORA Phase 3 Study Demonstrates Voclosporin Statistical Superiority Over Standard of Care in Lupus Nephritis (LN). Lupus Science and Medicine. 2020. 7(suppl 1).
Kolic J, Beet L, Overby P, Cen HH, Panzhinskiy E, Ure DR, Cross JL, Huizinga RB, Johnson JD. 2020. Differential Effects of Voclosporin and Tacrolimus on Insulin Secretion from Human Islets. Endocrinology. 161(11):bqaa162.
Link: 2020 Manuscript
Ginzler E, Saxena A, Bal V, Birardi V, Leher H. Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).
Link: 2022 ACR Poster
Saxena A, Caster D, Almaani S, Rosales A, Leher H. Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).
Link: 2022 ACR Poster
Afshinnia F, Rehaume LM, Cross JL, Huizinga RB, Pennathur S: Voclosporin Therapy Induces Systemic Lipidomic Alterations: Implications for Lipid Mediators for Remission of Lupus Nephritis. J Am Soc Nephrol 33, 2022: Page 792.
Afshinnia F, Rehaume LM, Cross JL, Huizinga RB, Pennathur S: Voclosporin Therapy Induces Systemic Lipidomic Alterations: Implications for Lipid Mediators for Remission of Lupus Nephritis. J Am Soc Nephrol 33, 2022: Page 792.
Link: 2022 ASN Abstract
Parikh S, Arriens C, Hodge L, Mela C, Leher H: Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome Over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies. J Am Soc Nephrol 33, 2022: Page 184.
Link: 2022 ASN Poster
Caster D, Saxena A, Almaani S, Rosales A, Leher H: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study. J Am Soc Nephrol 33, 2022: Page 498.
Link: 2022 ASN Poster
Tagoe KJ, Orujov E, Baker MG, Cipolla L, McLemore J, Leher H: Enlight-LN: A Prospective Observational Registry of Patients Treated with Voclosporin for Lupus Nephritis in the United States. J Am Soc Nephrol 33, 2022.
Link: 2022 ASN Poster
Tatsuya Atsumi, Tien-Tsai Cheng, Tuyen Do Gia, Shunsuke Furuta, Harold Michael P. Gomez, Llewellyn T. Hao, Ngoc Phuong Thao Huynh, Michihito Kono, Sandra Navarra, Kajohnsak Noppakun, Kenji Oku, Bernadette Reyes, Bancha Satirapoj: Long-term Safety and Efficacy of Voclosporin in Asian Patients with Lupus Nephritis. APLAR. 2022.
American Society of Nephrology – Kidney Week 2020: Linear PK TDM. Use of Therapeutic Drug Monitoring Does Not Add Clinical Value for Voclosporin in Patients with Lupus Nephritis. Teun van Gelder, Robert B. Huizinga, Jan Noukens, Laura Lisk, and Neil Solomons.
American Society of Nephrology – Kidney Week 2020: Pooled AURA-LV and AURORA. Management of Lupus Nephritis with Voclosporin: An Update from a Pooled Analysis of 534 Patients. Brad H. Rovin, Samir V. Parikh, Robert B. Huizinga, Neil Solomons and Simrat Randhawa for the AURORA Study Group.
American Society of Nephrology – Kidney Week 2020: Linear PK TDM. Use of Therapeutic Drug Monitoring Does Not Add Clinical Value for Voclosporin in Patients with Lupus Nephritis. Teun van Gelder, Robert B. Huizinga, Jan Noukens, Laura Lisk, and Neil Solomons.
American Society of Nephrology – Kidney Week 2020: Pooled AURA-LV and AURORA. Management of Lupus Nephritis with Voclosporin: An Update from a Pooled Analysis of 534 Patients. Brad H. Rovin, Samir V. Parikh, Robert B. Huizinga, Neil Solomons and Simrat Randhawa for the AURORA Study Group.